Medical authorship and transparent review
The established Cancer Aware medical-content credit is Dr Hakeem Ansar Hussain, Medical Oncologist. This cervical guide was prepared with AI assistance. Evidence and editorial checking was performed during preparation on 26–28 October 2026. No individual physician sign-off for these newly added pages is recorded; the site does not claim that the clinician has personally checked each sentence.
What was checked
The review focused on FIGO staging boundaries, screening and vaccination differences, fertility and surgical selection, brachytherapy, immunotherapy settings, trial populations and outcomes, and regional regulatory distinctions. Primary trial reports, WHO, Indian government, NCI, FIGO, ESGO/ESTRO/ESP, ASCCP, ACS, USPSTF, HRSA, FDA and EMA sources are linked below and in the relevant chapters.
The current full licensed NCCN and ESMO professional texts were not comprehensively accessed line by line. This guide therefore does not claim complete verification against every October 2026 guideline version or every country's drug label. Treating clinicians should check their current local professional guidance, approvals and reimbursement.
How to read the evidence
Trial efficacy is different from a regulatory indication, and an approval in one jurisdiction is not worldwide approval. Older FIGO trial eligibility must not be relabelled using newer staging without reviewing the actual disease extent. Survival statistics describe populations and cannot give an individual's prognosis. Educational tools do not issue screening orders, assign a clinical stage or prescribe treatment.
Updates and corrections
Clinician review should record the reviewer's name, actual date, scope and any corrections before the review status is changed. New guidance, label changes or errors should trigger revision of both the chapter and linked tool. Publication and an evidence-check date do not constitute physician endorsement of an unreviewed change.
Urgent symptoms
Heavy bleeding with faintness, chest pain, sudden breathlessness, confusion or severe uncontrolled pain requires urgent medical care. Fever during chemotherapy, severe diarrhoea, dehydration or new symptoms on immunotherapy require immediate contact with the treating team. Do not wait for a website response.
References and review status
- NCI — Cervical cancer treatment PDQ (professional evidence summary)
- Bhatla et al. Cancer of the cervix uteri: FIGO Cancer Report 2025
- Cibula et al. ESGO/ESTRO/ESP cervical cancer guidelines, 2023 update
- WHO — Cervical cancer fact sheet
- CDC — HPV vaccination recommendations and considerations
- NCI — HPV and Pap test results: next steps
- NCI — Cervical cancer prevention PDQ
- WHO — Updated HPV vaccination schedule, December 2022
- India Ministry of Health / PIB — National HPV vaccination launch, 28 February 2026
- WHO — Screening and treatment recommendations, 2021
- India national operational framework: management of common cancers
- American Cancer Society — Cervical screening guideline (December 2025 update)
- USPSTF — Cervical cancer screening: final recommendation retrieved (2018)
- HRSA/WPSI — Final Women's Preventive Services Guidelines, 5 January 2026
- ASCCP — Risk-based management consensus guidelines and resources
- NCI — Cervical cancer symptoms
- NCI — Cervical cancer diagnosis
- NCI — Cervical cancer stages
- NCI — Cervical cancer treatment overview
- NCI — Support for people with cancer and families
- Plante et al. SHAPE: simple versus radical hysterectomy, NEJM 2024
- Ramirez et al. LACC: minimally invasive versus abdominal radical hysterectomy, NEJM 2018
- NCI — Fertility issues in girls and women with cancer
- NCI — Radiation therapy for cancer
- EMBRACE — Image-guided adaptive brachytherapy research and protocols
- Lorusso et al. KEYNOTE-A18 overall survival analysis, Lancet 2024
- FDA — Pembrolizumab with chemoradiotherapy, FIGO 2014 III–IVA, January 2024
- McCormack et al. INTERLACE randomized phase III trial, Lancet 2024
- Mileshkin et al. OUTBACK randomized phase III trial, Lancet Oncology 2023
- Monk et al. KEYNOTE-826 final overall survival, Journal of Clinical Oncology 2023
- FDA approval announcement reproduced by ASCO, October 2021
- NCI — Immunotherapy side effects
- Tewari et al. GOG-240 final survival analysis, Lancet 2017
- Tewari et al. EMPOWER-Cervical 1, NEJM 2022
- EMA — Libtayo (cemiplimab), current authorized indications
- Coleman et al. innovaTV 204 phase II study, Lancet Oncology 2021
- Vergote et al. innovaTV 301 randomized phase III trial, NEJM 2024
- FDA — Tisotumab vedotin regular approval, April 2024
- NCI — Targeted cancer therapies
- NCI — Clinical trials information for patients
- NCI — Side effects of cancer treatment
- NCI — Nutrition during cancer treatment
- NCI — Fatigue and cancer treatment
- NCI — Follow-up medical care after cancer treatment
- NCI SEER — Cervical cancer statistics, 2016–2022 survival cohort
- NCI — Understanding cancer prognosis
Evidence/editorial check: 28 October 2026. AI-assisted preparation is separate from physician sign-off. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy